Navigation Links
Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
Date:9/5/2007

Live Audio Webcast Friday, September 7, 2007

SAN DIEGO, Sept. 5 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Neurocrine Biosciences will present at the Thomas Weisel Partners Healthcare Conference. The live presentation takes place Friday, September 7, 2007 at 11:30 a.m. Eastern Time (ET) /8:30 a.m. Pacific Time (PT). The presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be archived on the website for two weeks.

About Neurocrine

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical Company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, endometriosis, pain, irritable bowel syndrome, and autoimmunity. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... , Dec. 7, 2016  Biocom, the association for the ... statement below following passage of 21 st Century Cures ... November 30 by a 392-26 vote and in the Senate ... be attributed to Joe Panetta , president & CEO ... will give hope to millions of patients around the world. ...
(Date:12/7/2016)...  Genprex, Inc. a biopharmaceutical company focused on ... announced that it has retained ICR Healthcare, a ... and advisory firm, to develop and implement an ... investor relations, public relations and digital communications to ... Genprex and its lead candidate Oncoprex, which is ...
(Date:12/7/2016)... Regen BioPharma Inc. (OTCQB: RGBPP) In a recent ... team of scientists in Guangzhou, China ... of NR2F6 in patients with early cervical cancer correlates with ... cancer tissue as well as in the normal tissue surrounding ... study and the first that I am aware of that ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... --  Avanade is helping Williams Martini Racing, one ... exploit biometric data in order to critically analyse every ... edge against their rivals after their impressive, record-breaking pit ... worked with Williams during the 2016 season to capture ... breathing rate, temperature and peak acceleration) for key members ...
(Date:12/6/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... of €500.0 million principal amount of its 1.414% senior unsecured ... 2.425% senior unsecured notes due 2026. The ... 2016, subject to the satisfaction of customary closing conditions.  The ... The Company intends to use the net ...
Breaking Biology News(10 mins):